2021
Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents
Fisher B, Zaoutis T, Xiao R, Wattier R, Castagnola E, Pana Z, Fullenkamp A, Boge C, Ross R, Yildirim I, Palazzi D, Danziger-Isakov L, Vora S, Arrieta A, Yin D, Avilés-Robles M, Sharma T, Tribble A, Maron G, Berman D, Green M, Sung L, Romero J, Hauger S, Roilides E, Belani K, Nolt D, Soler-Palacin P, López-Medina E, Muller W, Halasa N, Dulek D, Bin Hussain I, Pong A, Hoffman J, Rajan S, Gonzalez B, Hanisch B, Aftandilian C, Carlesse F, Abzug M, Huppler A, Salvatore C, Ardura M, Chakrabarti A, Santolaya M, Localio A, Steinbach W. Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents. Journal Of The Pediatric Infectious Diseases Society 2021, 10: 994-1003. PMID: 34374424, DOI: 10.1093/jpids/piab024.Peer-Reviewed Original ResearchAmphotericin B formulationsInvasive candidiasisAmphotericin B groupRisk differenceExposure groupB formulationsMultinational observational cohort studyCommon invasive fungal diseaseCrude failure rateData review committeeObservational cohort studyB groupInvasive fungal diseaseMantel-Haenszel analysisCohort studyPrimary outcomePrimary exposureFailure rateComparative effectivenessCandidiasisTherapyEffectiveness dataEchinocandinsReview CommitteeChildren
2020
Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole
Bernardo V, Miles A, Fernandez AJ, Liverman R, Tippett A, Yildirim I. Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole. Pediatric Transplantation 2020, 24: e13777. PMID: 32639095, DOI: 10.1111/petr.13777.Peer-Reviewed Original ResearchConceptsYears of ageMedian daily doseTrough concentrationsDaily dosePlasma concentrationsYoung adultsPlasma trough concentrationsSerum posaconazole concentrationsInvasive fungal diseaseTherapeutic plasma concentrationsDelayed-release tabletsIntravenous posaconazolePosaconazole dosingImmunocompromised childrenPatients 13Optimal dosingBroad-spectrum antifungalsAdolescent patientsPosaconazole concentrationsHigher dosingPatientsBody weightGrade 1ProphylaxisDosing